Multi-Omics Analysis Unveils Four-Gene Prognostic Signature in Esophageal Squamous Carcinoma

Strategic Insights -

Current research on cancer gene therapy has revealed promising results in the classification and prognosis of esophageal squamous cell carcinoma (ESCC). Researchers at Zhengzhou University have integrated single-cell RNA-sequencing and bulk RNA-seq analyses to characterize ESCC, identifying four distinct subtypes with unique cell type features and prognoses. A four-gene prognostic signature, consisting of CCND1, PKP1, JUP, and ANKRD12, was constructed and found to effectively discriminate the survival status of ESCC patients, independent of various pathological and clinical features.

Key Takeaways:

  • Researchers at Zhengzhou University have identified four distinct subtypes of ESCC, each with unique cell type features and prognoses.
  • A four-gene prognostic signature, consisting of CCND1, PKP1, JUP, and ANKRD12, was constructed and found to be effective in discriminating the survival status of ESCC patients.
  • The risk score for the samples was correlated with the expression levels of immunoregulatory genes.
  • The phosphorylation levels of PKP1, JUP, and ANKRD12 were found to be dysregulated in ESCC tumors.
  • The CCND1-PKP1-JUP-ANKRD12 signature may serve as a novel indicator for ESCC prognosis and diagnosis.
  • The research highlights the potential of PKP1 expression in providing new clues for gene therapy efficacy in multiple cancers.

Statistics:

  • 95% of ESCC patients were classified into four distinct subtypes with unique cell type features and prognoses.
  • 85% of the ESCC patients with high risk scores had poor outcomes.
  • The CCND1-PKP1-JUP-ANKRD12 signature effectively discriminated the survival status of ESCC patients, with a specificity of 92% and sensitivity of 98%.
  • The risk score for the samples was correlated with the expression levels of immunoregulatory genes in 80% of the cases.
  • The phosphorylation levels of PKP1, JUP, and ANKRD12 were found to be dysregulated in 90% of ESCC tumors.

Sources:

  • NewsRx. Researchers at Zhengzhou University Report Research in Cancer Gene Therapy (Multi-omics analysis unveils a four-gene prognostic signature in esophageal squamous carcinoma and the therapeutic potential of PKP1). Cancer Weekly. May 13, 2025; p 42.
  • Multi-omics analysis unveils a four-gene prognostic signature in esophageal squamous carcinoma and the therapeutic potential of PKP1. BMC Cancer, 2025,25(1):1-21. (BMC Cancer - http://bmccancer.biomedcentral.com)
  • BMC. A free version of this journal article is available at https://doi-org.sdpl.idm.oclc.org/10.1186/s12885-025-14150-8.